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ABSTRACT
Objective Keratin (K)19, a biliary/hepatic progenitor
cell (HPC) marker, is expressed in a subset of
hepatocellular carcinomas (HCC) with poor prognosis.
The underlying mechanisms driving this phenotype of
K19-positive HCC remain elusive.
Design Clinicopathological value of K19 was compared
with EpCAM, and α-fetoprotein, in a Caucasian cohort
of 242 consecutive patients (167 surgical specimens, 75
needle biopsies) with different underlying aetiologies.
Using microarrays and microRNA profiling the molecular
phenotype of K19-positive HCCs was identified. Clinical
primary HCC samples were submitted to in vitro invasion
assays and to side population analysis. HCC cell lines
were transfected with synthetic siRNAs against KRT19
and submitted to invasion and cytotoxicity assays.
Results In the cohort of surgical specimens, K19
expression showed the strongest correlation with
increased tumour size (p<0.01), decreased tumour
differentiation (p<0.001), metastasis (p<0.05) and
microvascular invasion (p<0.001). The prognostic value
of K19 was also confirmed in a set of 75 needle
biopsies. Profiling showed that K19-positive HCCs highly
express invasion-related/metastasis-related markers (eg,
VASP, TACSTD2, LAMB1, LAMC2, PDGFRA), biliary/HPC
markers (eg, CD133, GSTP1, NOTCH2, JAG1) and
members of the miRNA family 200 (eg, miR-141, miR-
200c). In vitro, primary human K19-positive tumour cells
showed increased invasiveness, and reside in the
chemoresistant side population. Functionally, K19/KRT19
knockdown results in reduced invasion, loss of
invadopodia formation and decreased resistance to
doxorubicin, 5-fluorouracil and sorafenib.
Conclusions Giving the distinct invasive properties, the
different molecular profile and the poor prognostic
outcome, K19-positive HCCs should be considered as a
seperate entity of HCCs.
INTRODUCTION
The expression of keratin (K)19, a marker for cho-
langiocytes, hepatic progenitor cells (HPCs) and
early hepatoblasts, has been linked with a poor
prognosis for patients diagnosed with hepatocellu-
lar carcinoma (HCC).1 Over the past years, many
Eastern studies, mainly on HBV-infected patients,
associated the occurrence of K19 with clinico-
pathological features, such as metastasis, poor
tumour differentiation, tumour recurrence after
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Significance of this study
What is already known on this subject?
▸ Keratin (K)19, a biliary/hepatic progenitor cell (HPC)
marker, is expressed in a subset of hepatocellular
carcinomas (HCC) with poor prognosis, and is
thought to reflect the cell of origin.
▸ Over the past years, many Eastern studies,
mainly on HBV infected patients, have
associated the occurrence of K19 with
clinicopathological features, such as metastasis,
poor tumour differentiation, tumour recurrence
after resection and radiofrequency ablation, as
well as poor overall survival.
▸ In 2006, our group was the first to describe the
clinicopathological and prognostic relevance of
K19 in a Caucasian series of HCCs as it was linked
with a high recurrence after transplantation.
What are the new findings?
▸ In this prospective Caucasian series of 242
consecutive HCCs, K19 expression was most
strongly correlated with clinicopathological
parameters, in comparison with EPCAM and
α-fetoprotein, including increased tumour size,
decreased tumour differentiation, metastasis
and microvascular invasion.
▸ Thorough molecular profiling (including mRNA
and microRNA arrays) revealed a novel
regulatory network associated with K19
expression which, in turn, intersected with
pathways controlling cytoskeleton dynamics
and cellular motility. microRNA overexpression
confirmed a role for several novel candidate
microRNAs (eg, miR-141, miR-200c) in
modulating K19-associated genes.
▸ We further demonstrated in vitro, using primary
human HCC samples, that K19 expression confers
an invasive phenotype. K19 expression was also
associated with chemoresistance, which was
demonstrated using the side population cell
isolation technique and cytotoxic assays.
▸ Our findings demonstrate functional
consequences of K19 expression, since KRT19
knockdown significantly reduced HCC invasive
ability in vitro and compromised the formation of
invadopodia.
674 Govaere O, et al. Gut 2014;63:674–685. doi:10.1136/gutjnl-2012-304351
Hepatology
group.bmj.com on December 8, 2017 - Published by http://gut.bmj.com/Downloaded from 
resection and radiofrequency ablation, as well as poor overall
survival.2–6 In 2006, our group was the first to describe the clin-
icopathological and prognostic relevance of K19 in a Caucasian
series of HCCs as it was linked with a high recurrence after
transplantation.7 Subsequently, we started a prospective study
on a Caucasian series of 242 consecutive HCC samples with a
different range of aetiologies and performed a detailed evalu-
ation of the clinicopathological relevance of K19.
Although various publications describe the prognostic rele-
vance of K19 in HCCs, it remains unclear why these particular
tumours behave more aggressively. One hypothesis finds its
explanation in the possible cell of origin.8 Approximately 80%
of HCCs arise on a background of long-lasting chronic liver
disease, where there is an extensive activation of the HPC com-
partment. Bipotential HPCs have the capacity to differentiate
into hepatocytes or cholangiocytes to facilitate liver regener-
ation, but their activation and proliferation also provide a poten-
tial source for carcinogenesis. In humans, the description of
primary hepatic carcinomas with mixed hepatocellular/cholan-
giocellular features and HCCs displaying progenitor/stemness
features, at least supports the idea that some primary liver
cancers arise from HPCs.9 HPCs are thought to be resilient and
to be able to survive in a chronic diseased liver, an environment
full of inflammation, oxidative stress and necrosis, due to their
high expression of ATP-binding cassette (ABC) transporters.10
ABC transporters protect the cell by actively transporting a wide
variety of substrates (including xenobiotics) across the cell mem-
brane, using ATP during the process, but also contribute to mul-
tidrug chemoresistance, rendering tumour cells resistance to
systemic therapies.11 Several of these ABC transporters are
reported to colocalise with K19 expression in HCCs, suggesting
that K19-positive HCCs and HPCs share similar protective
mechanisms.10
In this present study, we assess the clinicopathological rele-
vance of K19 in a Caucasian series of 242 consecutive HCC
samples in comparison with other biliary/HPC markers, epi-
thelial cell adhesion molecule (EpCAM) and α-fetoprotein
(AFP), and we also unravel the underlying molecular pheno-
type of K19-positive HCCs, using microarrays and microRNA
(miRNA/miR) profiling. Several of these miRNAs were shown
to contribute to the K19-positive phenotype. Trying to
further elude the more aggressive behaviour of these tumours,
clinical human HCC samples were submitted to in vitro inva-
sion assays and to side population (SP) cell isolations, a tech-
nique used to isolate a chemoresistant subpopulation based on
the ability of ABC transporters to efflux Hoechst33342.
Finally, the functional role of K19 and its effect to associated
genes was evaluated in relationship to invasion and resistance
to cytotoxic agents.
METHODS
Patient selection
The diagnosis of HCC was based on WHO criteria. Totally, 242
formalin-fixed paraffin-embedded (FFPE) liver biopsies from
242 consecutive patients with HCC, treated at the University
Hospitals Leuven between 2003 and 2008, were included. The
242 samples were divided into two groups, consisting of 167
surgical specimens and 75 needle biopsies. In case of multiple
nodules per patient (eg, satellite nodules in explant livers), the
largest HCC nodule was selected as representative sample for
the patient. For the surgical specimens, the tumour size was
measured macroscopically after the removal of the sample;
tumour differentiation and microvascular invasion was graded
based on histopathological evaluation. Microvascular invasion
was scored in the tumour and in the surrounding tissue of the
tumour. Positivity for metastasis was established using histo-
pathological evaluation and/or based on available clinical data
(126 of the 167). Needle biopsies were taken for diagnostic
purpose or before a surgical procedure (eg, radiofrequency
ablation) and were scored for microvascular invasion and differ-
entiation grade similar to the surgical specimens. Metastasis
was analysed solely based on the available clinical data (17 of
the 75). Tumour size for the needle biopsies was not
established.
K19, EPCAM and AFP expression was semiquantitatively
assessed by means of immunohistochemistry on consecutive
FFPE slides. Samples were considered positive for a marker
when expression was seen, using a cut-off value of 5% immuno-
histochemical positivity to exclude false positives, as previously
described.7 Contingency analysis was done using the Fisher’s
Exact test and the unpaired t test with STATVIEW 5.0.1 soft-
ware (SAS Institute, Cary, North Carolina, USA). The study was
approved by the ethical committee of the University Hospitals
Leuven.
Immunohistochemistry and in situ hybridisation
Of the 242 HCC samples stained for K19 (1/25; Dako, Glostrup,
Denmark), EPCAM (1/50; Dako) and AFP (1/500; Dako), a
subset (K19-positive and -negative n=12 per group) was selected
as a validation set for some selected targets: laminin (1/50;
Novocastra, NewCastle, UK), VASP (1/100; Sigma–Aldrich, St
Louis, Missouri, USA), PDGFRA (1/50; Abcam, Cambridge, UK)
and TACSTD2 (1/20; Abcam). Immunohistochemistry/immuno-
cytochemistry was performed as previously described.10 12 In
situ hybridisation was performed with DIG-labelled probes
against hsa-miR-141 and hsa-miR-200c (Exiqon, Vedbaek,
Denmark) as reported previously.13
Microarray analysis
Microarray analysis was performed on 139 HCC samples
(GSE1898 and GSE4024).14 15 Gene expression profiles were
generated at the Advanced Technology Centre (National Cancer
Institute, USA). Data transformation and normalisation of gene
expression was performed as previously reported. Association
with clinicopathological features and statistical analysis are
described in online supplementary file 1. Gene Set Enrichment
Analysis was used to statistically analyse the overlap of KRT19
correlated genes with previous published gene expression
signatures (see online supplementary files 2 and 3). 16 17
Additionally, STRING analysis was performed to predict pos-
sible interactions, either direct (physical) or indirect (func-
tional) associations.18
Significance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ Our data sheds new light on the mechanisms underlying the
poor prognostic K19 phenotype, and strongly supports the
contention that K19-positive HCC should be diagnosed and
treated as a separate entity of HCCs.
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Quantitative real-time PCR (qPCR)
qPCR Was performed on a subset of 12 frozen HCC resection
specimens, K19-positive (n=6) or -negative (n=6), diagnosed at
the University Hospitals Leuven Belgium. RNA extraction,
cDNA synthesis and qPCR analysis were performed as previ-
ously described.12 Overview of custom-designed primer
sequences can be found in online supplementary file 4.
Invasion assay and SP analysis
Tissue samples obtained from patients diagnosed with HCC
(K19-positive n=6, negative n=6) at the University Hospitals
Leuven between 2008 and 2011 were cryopreserved postsurgery
and histopathologically characterised. Samples were dissociated
using LiberaseBlendzyme3 (Roche, Basel, Switzerland; 0.8
Wunsch unit/mL, 1.5 h, 37°C). After filtration and gradient cen-
trifugation, the cells were resuspended in Advanced Dulbecco’s
Modified Eagle’s Medium supplemented with L-Glutamine
(Invitrogen, Carlsbad, California, USA) and submitted to a
QCM ECMatrix Cell Invasion Assay (Millipore, Billerica,
Massachusetts, USA; 8 μm). Fetal bovine serum (Invitrogen) was
used as chemoattractant. After 48 h, invaded cells were detected
by crystal violet stain and quantified at an optical density (OD)
of 560 nm. Parallel, invaded cells were immunostained after
48 h for K19, as described above.
To assess active efflux and SP phenotype, dissociated HCC
cells were incubated with or without the transport blocker ver-
apamil (100 μM; Sigma–Aldrich), prior to the Hoechst33342
incubation (5 mg/mL; Sigma–Aldrich) as previously reported.
Propidium iodide (2 mg/mL; Sigma–Aldrich) was added to
exclude dead cells. Cell suspensions were analysed using a
FACSAriaII (BDBiosciences). A detailed description of the dis-
sociation protocol and SP method can be found in online sup-
plementary file 4.
In vitro transient knockdown of KRT19/K19
Human HCC cell lines HepG2, Huh-7D12, PLC/PRF/5
(ECACC, Salisbury, UK) were transfected using
ON-TARGETplus siRNA against KRT19 or ON-TARGETplus
Non-targeting siRNA at a final concentration of 25 nM
(Dharmacon, Lafayette, Colorado, USA), using Lipofectamine
RNAiMAX Transfection Reagent (Invitrogen). After 24 h, trans-
fected cells were submitted to a QCM ECMatrix Cell Invasion
Assay and a MTT Cell Growth Assay (Millipore) for 48 h.
Colorimetric reading of the Invasion Assay was done at
OD560 nm; the MTT Assay at OD570 nm using a reference
point of 630 nm. Results of invasion were normalised to the
proliferation results. In parallel, cells were transfected and har-
vested after 72 h for total mRNA extraction and qPCR analysis.
In vitro stable knockdown of KRT19/K19
Huh-7D12 cells were transduced using SMARTvector 2.0
Human Lentiviral shRNA Particles KRT19, hCMV-TurboGFP or
SMARTvector 2.0 Empty Vector Control Particles, according to
supplier’s protocol (Dharmacon). Cells were submitted to the
QCM Gelatin Invadopodia Assay Green (Millipore) according
to supplier’s protocol. After 24 h, cells were fixated in acetone
for 10 min and stained for Cytokeratin Wide Spectrum
Screening (DAKO) for 60 min, followed by an incubation with
Alexa Fluor 568 Goat Anti-Rabbit (1/100, Invitrogen) for
30 min and counterstaining with DAPI (Invitrogen).
Additionally, Huh-7D12 cells with stable KRT19 knockdown
or control vector were treated with doxorubicin (1 mM),
5-fluorouracil (1 mM) and sorafenib (5 mM) (Selleckchem,
Texas, USA), supplemented to the culture medium for 72 h and
submitted to a MTTassay in comparison with untreated cells.
MicroRNA profiling and In vitro modulation
Genome-wide RT2 miRNA PCR Arrays (384-well based;
SABiosciences, Frederick, Maryland, USA) were performed on
frozen HCC liver biopsies (n=12), according to supplier’s proto-
col. Human HCC cell lines were characterised using RT2 miRNA
qPCR Primer Assays (SABiosciences). Normalisation of the cycle
threshold data was done to reference small RNA (U6, SNORD44,
47 and 48), fold-change was calculated based on the 2(−ΔΔCt)
method. The PLC/PRF/5 cell line was transfected (n=3) with
miRIDIAN Dharmacon microRNA Mimics (miR-141, miR-200c,
negative control) at a final concentration of 2 nM, using
DharmaFECT4 Transfection Reagent (Dharmacon), according to
supplier’s protocol. Cells were harvested after 48 h prior to total
mRNA extraction.
Statistical analysis
Statistical analysis for qPCR, MTT assays and invasion assays
was performed using the non-parametric Kruskal–Wallis and the
Man–Whitney U test, with Graphpad Prism 5.02 (GraphPad
Software, La Jolla, California, USA). All analyses were two-
tailed. In all cases, p<0.05 was considered significant.
RESULTS
Occurrence and clinicopathological relevance of HCC
prognostic markers
After our previous retrospective study, demonstrating an associ-
ation between K19 expression and HCC recurrence after trans-
plantation, we started a prospective study to further investigate
‘stemness’ features in HCC and the role of K19.7 Biliary/HPC
markers K19, EPCAM and AFP were compared and linked with
clinicopathological features in a cohort of 242 consecutive
patients, consisting of 167 surgical specimens and 75 needle
biopsies. In 167 surgical specimens, 11.38% showed K19 immu-
nopositivity (n=19), 14.97% EPCAM positivity (n=25) and
10.78% AFP positivity (n=18) (figure 1A). Only 2.99% (n=5)
showed simultaneous positivity for all three markers. In total,
62.87% of the HCCs were negative for all three markers
(n=105). Immunohistochemically, K19 showed a submembra-
nous and EPCAM a membranous localisation, whereas AFP
showed a diffuse cytoplasmic signal (figure 1B–D). K19 expres-
sion was significantly correlated with increased tumour size
(p<0.01), decreased tumour differentiation (p<0.001), metas-
tasis (p<0.05) and microvascular invasion (p<0.001) ((table 1).
AFP expression significantly correlated with decreased
tumour differentiation (p<0.001) and microvascular invasion
(p<0.001), whereas EPCAM only correlated with microvascular
invasion (p<0.05). The clinicopathological relevance of K19
expression was also significant in a cohort of 75 needle biopsies
(table 1). K19 expression was seen in 20% of the samples
(n=15) and was significantly linked with decreased tumour dif-
ferentiation (p<0.001), metastasis (p<0.05) and microvascular
invasion (p<0.01).
Molecular phenotype of K19-positive HCCs
In order to unravel the molecular/transcriptomic background of
K19-positive HCCs, and to discover K19-associated pathways,
we used a microarray database of 139 HCC samples. Similar to
K19 protein expression, KRT19 mRNA expression was signifi-
cantly associated with clinicopathological parameters and was
an independent predictor for tumour recurrence (Log rank test,
p=0.007; HR 1.70) (see online supplementary file 1).
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Out of 21 329 genes quantified by microarray, 132 genes cor-
related positively, and 203 genes negatively with KRT19 expres-
sion (see online supplementary file 2). Gene Set Enrichment
Analysis of the genes positively correlated with KRT19 showed a
strong correlation with several other cancer-related datasets,
including ‘poor survival HCC subtype’, ‘proliferation HCC
subtype’, ‘subtype S1 signature with aberrant Wnt activation’ (see
online supplementary file 3).16 Genes negatively correlated with
KRT19 showed a significant overlap with liver-/hepatocyte-
specific genes and genes downregulated in malignant HCC sub-
types (see online supplementary file 3). Additionally, STRING
analysis was performed to predict protein–protein interactions
among the genes that were positively correlated with K19 expres-
sion, in order to gain insight into the molecular mechanisms
underlying the aggressive nature of K19-positive HCCs.18 K19
was clearly linked with a node around the gene vasodilator-
stimulated phosphoprotein (VASP) and genes involved in the
extracellular matrix (ECM) (eg, VCL, LAMB1, LAMC2, ITGA3,
ITGB6) (see online supplementary file 3). qPCR Validation of
KRT19-correlated genes and selected candidates, confirmed that
K19-positive HCCs express high levels of other biliary/HPCs cell
markers (eg, KRT7, CD133, GSTP1) in addition to KRT19, when
compared with K19-negative HCCs (figure 2A). Moreover, we
observed strong upregulation of members of the Notch signalling
pathway (eg, NOTCH1, NOTCH2, NOTCH3, JAG1, JAG2),
reduced expression of hepatocyte-specific genes (eg, HNF4A,
ABCC2) and induction of invasion-related/metastasis-related
markers (eg, CTBP2, S100A6, VASP, FAM57A, TACSTD2,
ANXA3, RAB25, RAB27B). By contrast, the metastasis suppressor
MTSS1 was downregulated. We also observed alterations in
mRNAs encoding cytoskeletal regulators (upregulation of
IQGAP1 and downregulation of IQGAP2) and ECM components
(upregulation of LAMB1 and LAMC2) in K19-positive tumours.
Immunohistochemistry revealed that a large fraction of
K19-positive HCCs exhibited abundant cytoplasmic laminin, as
was observed in the basement membrane around HPCs and in
individual HPCs in the neighbouring cirrhotic tissue (figure 2B).
Additionally, K19-positive HCCs showed an intense submembra-
nous positivity for VASP and a membranous positivity for
platelet-derived growth factor receptor α (PDGFRA). Tumour-
associated calcium signal transducer 2 (TACSTD2/TROP2)
showed a membranous reactivity in a small portion of the HCCs
that were poorly differentiated and K19-positive. Morphologic-
ally, TACSTD2-positive tumour cells showed a more progenitor-
like phenotype with a high cell density and scant cytoplasm. In
the non-tumoural surrounding tissue, TACSTD2, VASP and
laminin were found to be mainly expressed by the HPCs and the
smaller bile ducts, whereas, the larger bile ducts showed a vari-
able, focal positivity for these proteins. PDGFRa, by contrast,
was expressed by all the biliary epithelial cells and the HPCs
(figure 2B, online supplementary file 5).
A functional role for K19 in invasion and chemoresistance
In view of the strong association between K19 expression and
microvascular invasion, and the high expression of invasion-
related genes, we evaluated the invasive potential of K19-positive
HCC cells in vitro. Dissociated primary human HCCs, selected
for K19 immunopositivity, were used (figure 3A). K19 positivity
was first assessed in FFPE tissue samples and subsequently in
cytospins processed from dissociated cells. Both K19-positive
and negative dissociated tumour cells were subjected to an ECM
cell invasion assay. Only invasive cells can migrate through the
Figure 1 Occurrence and clinicopathological relevance of K19, EPCAM and α-fetoprotein (AFP) in hepatocellular carcinomas (HCCs). (A) Out of the
167 surgical HCC specimens 11.38% showed K19 positivity (n=19), 14.97% EPCAM positivity (n=25), and 10.78% AFP positivity (n=18). Only
2.99% (n=5) showed simultaneous positivity for all three markers. (B–D) Immunohistochemistry of a HCC sample positive for K19 (B), EPCAM
(C) and AFP (D). K19 showed a submembranous positivity and EPCAM a membranous one, whereas, AFP showed a diffuse cytoplasmic positivity.
Scale bars 250 mm.
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Table 1 Correlation of K19, EPCAM and α-fetoprotein (AFP) expression with clinicopathological features of surgical hepatocellular carcinoma (HCC) samples (resection and explant) obtained from
167 patients
K19-positive HCCs K19-negative HCCs EPCAM-positive HCCs EPCAM-negative HCCs AFP-positive HCCs AFP-negative HCCs
Immunopositivity 11.38% (19/167) 88.62%(148/167) 14.97% (25/167) 85.03% (142/167) 10.78% (18/167) 89.22% (149/167)
Age (years) (mean) 60.05 (ns) 62.04 (ns) 58.2 (ns) 62.45 (ns) 58.94 (ns) 62.16 (ns)
Gender
Male 63.16% (12/19; ns) 74.32% (110/148; ns) 68% (17/25; ns) 63.94% (105/142; ns) 77.78% (14/18; ns) 72.48% (108/149; ns)
Female 36.84% (7/19; ns) 25.68% (38/148; ns) 32% (8/25; ns) 26.06% (37/142; ns) 22.22% (4/18; ns) 27.52% (41/149; ns)
Aetiology
HBV 15.79% (3/19; ns) 7.43% (11/148; ns) 20% (5/25; ns) 6.34% (9/142; ns) 22.22% (4/18; ns) 6.04% (9/149; ns)
HCV 5.26% (1/19; ns) 29.73% (44/148; ns) 12% (3/25; ns) 29.58% (42/142; ns) 22.22% (4/18; ns) 27.52% (41/149; ns)
HBV+HCV 0% (0/19; ns) 2.70% (4/148; ns) 0% (0/25; ns) 2.82% (4/142; ns) 0% (0/18; ns) 2.69% (4/149%; ns)
ALD 10.52% (2/19; ns) 16.22% (24; ns) 16% (4/25;ns) 15.49% (22/142; ns) 16.67% (3/18; ns) 15.44% (23/149; ns)
ALD+viral infection 5.26% (1/19; ns) 2.03% (3/148; ns) 4% (1/25; ns) 2.11% (3/142; ns) 0% (0/18; ns) 2.01% (3/149; ns)
Other 36.84% (7/19; ns) 27.70% (41/148; ns) 36% (9/36; ns) 27.46% (39/142; ns) 27.78% (5/18; ns) 30.2% (45/149; ns)
Unknown 26.32% (5/19; ns) 14.19% (21/148; ns) 12% (3/25; ns) 16.2% (23/142; ns) 11.11% (2/18; ns) 16.11% (24/149; ns)
Microvascular Invasion 100% (19/19; p=0.0001) 52.03% (77/148; ns) 76% (19/25; p=0.0423) 54.23% (77/142; ns) 100% (18/18; p=0.0001) 52.35% (78/149; ns)
Metastasis 83.33% (10/12; p=0.0207) 48.25% (55/114; ns) 58.82% (10/17; ns) 50.46% (55/109; ns) 76.92% (10/13; ns) 48.67% (55/113; ns)
Tumour size (cm. mean) 6.77 (p=0.0077) 4.5 5.27 (ns) 4.72 4.92 (ns) 4.79
Differentiation grade
Well 5.26% (1/19) 45.27% (67/148) 32% (8/25) 42.25% (60/142) 5.56% (1/18) 44.97% (67/149)
Moderate 36.84% (7/19) 36.84% (54/148) 28% (7/25) 38.03% (54/142) 38.89% (7/18) 36.24% (54/149)
Poorly 57.89% (11/19; p=0.0001) 18.24% (27/148; ns) 40% (10/25; ns) 19.72% (28/142; ns) 55.56% (10/18; p=0.0004) 18.79% (28/149; ns)
Cirrhosis
No 31.58% (6/19;ns) 23.65% (35/148; ns) 44% (11/25; ns) 21.13% (30/142; ns) 27.78% (5/18; ns) 24.16% (36/149; ns)
Yes 68.42% (13/19;ns) 75% (111/148; ns) 56% (14/25; ns) 77.46 % (110/142; ns) 72.22% (13/18. ns) 74.5% (111/149; ns)
Unknown 0% (0/19; ns) 1.35% (2/148; ns) 0% (0/25; ns) 1.41% (2/142; ns) 0% (0/18; ns) 1.34% (2/149; ns)
Correlation of K19 expression with clinicopathological features of needle biospies obtained from 75 patients.
K19 positive HCCs K19 negative HCCs
Immunopositivity 20% (15/75) 80% (60/75)
Age (years) (mean) 63.93 (ns) 64.13 (ns)
Gender
Male 66.67% (10/15; ns) 73.33% (44/60; ns)
Female 33.33% (5/15; ns) 26.67% (16/60; ns)
Microvascular Invasion 66.67% (10/15; p=0.007) 21.67% (13/60; ns)
Metastasis 100% (5/5; p=0.0048) 25% (3/12; ns)
Differentiation grade
Continued
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ECM layer and cling to the bottom of a polycarbonate mem-
brane. After 48 h, cells from human primary K19-positive HCCs
showed a higher invasiveness than cells from K19-negative
HCCs (p<0.01; n=12). Interestingly, especially the
K19-positive tumour cells invaded through the basement mem-
brane, as found by immunostaining (figure 3A).
To investigate the functional role of K19, we performed
siRNA knockdown experiments in three different HCC cell
lines: the Huh-7D12 cell line was characterised as a cell line
showing 100% K19 positivity, whereas HepG2 cells showed a
weak focal positivity in about 20% of the cells and the PLC/
PRF/5 cell line was negative (figure 3B). Using an invasion assay,
transient knockdown of KRT19 reduced the invasiveness of
Huh-7D12 after 72 h by 34.7% (p<0.01) when compared with
the negative control (scrambled siRNA). By contrast, no signifi-
cant differences in invasiveness were found in HepG2 and PLC/
PRF/5 (figure 3B). Given the altered invasive potential of
Huh-7D12, we further examined the effect of KRT19 knock-
down on the expression of genes identified above. A significant
reduction in CD133, VASP, LAMB1, IQGAP1, ROCK2 (p<0.05)
and NOTCH2, JAG1, RAB25 (p<0.01) expression was observed
(figure 3B). No significant differences were found in the expres-
sion levels of ANXA3, S100A6, HNF4A, PDGFRA, IQGAP2,
LAMC2, CTBP2 and TACSTD2. In keeping with the results of
the migration assay, stable transduction of Huh-7D12 cells with
the KRT19 shRNA construct resulted in decreased formation of
invadopodia, as tested in a GFP-conjugated gelatin degradation
assay (figure 3C).
In HCC cell lines, SP technique, a method based on the func-
tional ability of ABC transporters to efflux Hoechst33342, has
proven to be useful to isolate a chemoresistant cell fraction with
HPC features.19 In this study, we apply the SP technique to
further functionally characterise K19-positive HCCs in com-
parison with K19-negative HCCs. Results indicate that the SP
comprised a larger proportion in K19-positive HCCs (10.2%
±4.1; n=6) than in K19-negative HCCs (3.3%±2.4; n=6)
(figure 4A,B). Immunohistochemistry of cytospins from sorted
SP cells and bulk tumour cells (main population or MP) showed
that all K19-positive cells were located in the SP (figure 4C).
Additionally, impairing KRT19 expression in Huh-7D12 cells by
stable transduction with KRT19 shRNA constructs, rendered the
cells more sensitive to treatments with either 1 mM doxorubicin,
1 mM fluorouracil or 5 mM sorafenib than Huh-7D12 cells
transduced with the control construct (p<0.05; t=72 h, n=3).
The effect was measured compared with untreated cells, using a
MTTassay, and displayed as % viable cells (figure 4D).
MicroRNA 200 family is linked with KRT19/K19 expression
Finally, an alternative profiling approach based on microRNA
(miRNA/miR) expression was used to identify the K19-positive
HCC phenotype more in detail. K19-positive HCCs exhibited
a significantly higher expression of miR-141, miR-200c, miR-
199a-3p, miR-218, miR-429 and miR-214 than K19-negative
HCCs, whereas, miR-122, miR-885-5p, miR-148a, miR-519a,
miR-148b, miR-556-5p, miR-193b, miR-618, miR-548b-3p, miR-
10b and miR-566 were relatively underexpressed in K19-positive
HCCs (figure 5A).
The baseline expression levels of the most highly upregulated
miRNAs, miR-141 and miR-200c, and the most downregulated,
miR-885-5p and miR-122, were analysed in the HCC cell lines
Huh-7D12, HepG2 and PLC/PRF/5 by qPCR. The members of
the miR-200 family (miR-141/miR-200c) were strongly linked
with KRT19 expression, in particular, miR-141 (figure 5B). To
investigate the effect of these specific miRNAs on KRT19
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mRNA expression and KRT19-related genes, miR-141/
miR-200c mimics were induced in the PLC/PRF/5, a
K19-negative/KRT19-low HCC cell line. Transiently inducing
the expression of miR-141and miR-200c significantly upregu-
lated the expression of LAMC2, KRT19, KRT7, EPCAM, paral-
leling gene expression in K19-positive HCCs themselves, and
significantly reduced the expression of hepatocyte-specific
markers ALB and HNF4A (p<0.01) when compared with the
negative control (figure 5C).
In situ hybridisation confirmed the strong link between
miR-141 and K19 expression in human HCC samples and sur-
rounding tissue. Additional in situ hybridisation for the most
differentially upregulated miRNAs can be found in online sup-
plementary file 5.
DISCUSSION
In this present study, the clinicopathological relevance of K19
was assessed in a prospective Caucasian series of 242 consecu-
tive HCC samples, consisting of 167 surgical specimens and 75
needle biopsies. As reported previously in a South Korean HCC
cohort consisting mainly of samples from hepatitis B
virus-infected patients, we were able to confirm the prognostic
value of K19 expression in our Caucasian cohort with different
underlying aetiologies as it significantly correlated with tumour
size, decreased tumour differentiation, metastasis and micro-
vascular invasion. Despite the possible overestimation or under-
estimation of protein expression, we confirmed the prognostic
value of K19 expression in diagnostic needle biopsies.4 In this
study, EPCAM did not prove to have the same prognostic value
as K19. This could be explained by the fact that in regenerating
liver, EPCAM is a much broader marker than K19, as it also
marks the progeny of the HPCs, the intermediate hepatocytes,
similar to K7.20
In order to better understand the more aggressive behaviour
of K19-positive HCCs, we unravelled the underlying molecular
phenotype. The KRT19-associated gene signature showed a
strong overlap with that of other previously described more
malignant HCC subclasses, such as ‘poor survival HCC
subtype’, ‘proliferation HCC subtype’ and ‘subtype S1 signature
with aberrant Wnt activation’.14 21 22 In addition to the occur-
rence of other HPC/biliary markers (eg, PROM1/CD133,
GSTP1, KRT7), K19-positive HCCs expressed a whole range of
invasion-related/metastasis-related genes, of which some proved
to be present in the surrounding non-neoplastic HPCs (eg,
TACSTD2, VASP, PDGFRA).12 23 24 To date, it is not clear
whether the expression of HPC markers in human HCCs is a
result of dedifferentiation of malignant hepatocytes during con-
tinuous mutagenesis, or whether this is the conserved ‘finger-
print’ of a HPC tumour origin. Direct evidence for the
involvement of HPCs in the histogenesis of HCC has been
found by Dumble et al, by isolating HPCs from p53 null
mice.25 In human chronic liver disease, our group described
that about half the preneoplastic small-cell dysplastic foci con-
sisted almost completely of cells that have the immunophenoty-
pic profile of HPCs and intermediate hepatocyte-like cells,
suggesting that HPCs can give rise to HCCs in human liver.26 In
this present study, the expression of similar markers in HPCs
and K19-positive HCCs is compatible with a HPC origin. The
aberrant expression of the Notch pathway at least insinuates
that HPCs and K19-positive HCC cells share some common
Figure 2 Molecular phenotype of K19-positive hepatocellular carcinomas (HCCs). (A) qPCR validation for a selected number of genes on
K19-positive (n=6) and -negative (n=6) HCCs. Genes were selected based on the Pearson correlation coefficient and/or pathway association. Results
are depicted as fold regulation (n-fold) of K19-positive versus K19-negative samples (**p<0.01; *p<0.05). (B) Immunohistochemical staining for
laminin, VASP, PDGFRA and TACSTD2 (scale bars 100 mm). Left panel shows a representative example of a K19-positive HCC, middle panel a
K19-negative HCC, right panel shows the surrounding tissue with extensive hepatic progenitor cell (HPC) activation (HPC, arrow; bile duct, asterisk).
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activated pathways.27 Our recent insights in the role of Notch
signalling in liver regeneration showed that activation of the
Notch pathway is pivotal for differentiation towards biliary cell
fate.28 Additionally, a strong cytoplasmic expression of laminin
was observed in K19-positive HCCs, as noted in areas of non-
neoplastic HPCs in the surrounding tissue. In human liver
disease, laminin has been reported to be part of the basement
membrane surrounding the HPCs in order to help them remain
in an undifferentiated state, indicating that K19-positive HCCs
might produce laminin to maintain their ‘stemness’.29
MicroRNA profiling and functional validation in cell lines, like-
wise, illustrated how members of the miR-200 family (eg,
miR-141/miR-200c) are strongly linked with K19/KRT19
expression. In vitro modulation of these particular miRNAs in a
K19-negative/KRT19-low HCC cell line actually induced the
expression of biliary/HPC markers and, moreover, the expres-
sion of LAMC2. It is possible that miR-141 and miR-200c con-
tribute to the HPC microenvironment and ‘stemness’ through
modulation of laminin.
K19-positive HCCs express more invasion-related/metastasis-
related genes compared with the K19-negative HCCs, and they
also showed an increased invasive capacity in vitro. Moreover,
keratin 19 positive tumour cells, in particular, exhibited the highest
invasive capacity. The role of the cytoskeleton and associated pro-
teins as cellular integrators in the neoplastic process has already
been suggested back in 1985.30 Our findings demonstrate func-
tional consequences of K19 expression, since KRT19 knockdown
significantly reduced HCC invasive ability in vitro and
Figure 3 A role for keratin 19 in tumour invasion. The ability of tumour cells to invade is one of the hallmarks of the metastatic phenotype.
(A) Human dissociated hepatocellular carcinomas (HCC) were subjected to an extracellular matrix (ECM) cell invasion assay. After 48 h, cells from
human primary K19-positive HCCs showed a higher invasiveness than cells from K19-negative HCCs (p<0.01; n=12). Immunostaining showed an
increase in K19-positive tumour cells after invasion, as compared with the original tumour. (B) Huh-7D12, PLC/PRF/5 and HepG2 HCC cell lines were
characterised by means of immunocytochemistry (left panel, scale bars 100 mm). After 72 h, the MTT assay showed no significant differences in
proliferation between KRT19/K19 knockdown and control (n=3); the knockdown only significantly reduced relative invasiveness of Huh-7D12 with
34.7%. Immunohistochemistry for K19 shows the decline of expression in transfected Huh-7D12 cells (scale bars 100 mm).The effect of the transient
knockdown on the expression of KRT19-associated genes was done by qPCR (displayed as relative fold expression) (**p<0.01; *p<0.05). (C) Stably
transduced Huh-7D12 cells were submitted to a QCM Gelatin Invadopodia Assay (24 h). The transduced cells were seeded onto green
fluorescein-conjugated gelatin substrates and after 24 h visualised with wide-spectrum cytokeratin (red) and DAPI (blue). Gelatin degradation
demonstrated that both the KRT19 knockdown as the negative control still possess invasive capacity, although cells transduced with a construct
against KRT19 showed less intense positivity for cytokeratin wide-spectrum screening (left panel, scale bars 100 mm). Invaded cells with reduced
KRT19/K19 expression demonstrated a decreased formation of invadopodia and regular cell morphology, compared with the negative control (right
panel, scale bars 50 mm).
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compromised the formation of invadopodia. A possible explan-
ation could be found in the influence of K19 on VASP and LAMB1.
VASP, a regulator of filopodia formation, has been reported to play
a role in adhesion dynamics and migration by actively linking the
cytoskeleton to the ECM in an integrin-dependent manner,
whereas LAMB1, known to interact with integrin receptors, has
been associated with tumour invasion.31 32 Considering the effect
of K19 on these specific genes, we hypothesise that K19 is a key
element in the transmembrane crosstalk between the cytoskeleton,
filopodia formation and the ECM.
Resistance to chemotherapy is commonly seen in the treat-
ment of HCC and is associated with cancer relapse and metasta-
sis. Multidrug resistance is frequently due to high ABC
transporter expression, enabling resistant cells to efflux poten-
tially harmful substances; thereby conferring a survival advan-
tage. SP analysis is an isolation technique that differentiates cell
populations based on ABC transporter function.33 This
technique was first reported by Goodell et al34 for the isolation
of murine haematopoietic stem cells with long-term multilineage
repopulating potential. In human HCC cell lines, SP isolation
has proven to be a useful approach to sort cells with a ‘stemness’
signature with increased tumour-initiation capacity and a higher
resistance to cytotoxic agents (eg, doxorubicin, 5-fluorouracil
and gemcitabine) compared with the non-SP fraction.19 35 36
These stem cell-like cancer cells are believed to provide hetero-
geneity to the cancer cell system. This cancer stem cell concept
has enormous implications for cancer therapy. Most treatments
target the rapidly dividing differentiating cells that comprise
the major bulk of tumours, often leading to significant reduction
in tumour size, although without eliminating the driving
force in tumour progression, the resistant cancer stem cells. In
this study, the SP fraction was significantly larger in the
K19-positive HCCs compared with K19-negative HCC, and,
most importantly, contained all the cells expressing K19. This
Figure 4 Keratin 19 and treatment resistance. Side population (SP) is based on the ability of stem-like cells to efflux the fluorescent DNA-binding
dye Hoechst 33342. The phenotype was obtained using the ATP-binding cassette-transporter blocker verapamil. (A) Using flow cytometric analysis,
a SP was cell sorted from the rest of the main population (MP), differing from an average of 3.3% (±2.4) in human K19-negative hepatocellular
carcinomas (HCC) (n=6) to 10.2% (±4.1) in human K19-positive HCCs (n=6) of the total viable cells. (B) A representative example of the SP plot
of a human K19-positive and K19-negative HCC. (C) Immunocytochemistry on cytospins of sorted cells showed that all the K19-positive cells were
located in the SP (scale bar formalin-fixed paraffin-embedded (FFPE) sample 200 mm; scale bars cytospins 100 mm). (D) Stably transduced
Huh-7D12 cells were treated with either 1 mM doxorubicin, 1 mM fluorouracil or 5 mM sorafenib (n=3) for 72 h. The effect was measured compared
with untreated cells, using a MTT assay, and displayed as % viable cells. Cells stably transduced against KRT19/K19 show a decreased viability when
treated for the selected agents as compared with the negative control (*p<0.05).
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Figure 5 MicroRNA profiling of K19-positive hepatocellular carcinomas (HCC). (A) MiRNA profiling of K19-positive (n=6) and -negative HCCs
(n=6). Results are depicted as fold regulation (n-fold) of K19-positive versus K19-negative samples (**p<0.01; *p<0.05). (B) Characterisation of
Huh-7D12, PLC/PRF/5 and HepG2 HCC cell lines for KRT19 and the most differentially expressed miRNAs found in the human samples (eg,
hsa-miR-141, hsa-miR-200c, hsa-miR-122 and has-miR-885-5p) was done by means of qPCR. Results are depicted as fold expression compared to
housekeeping genes/nuclear microRNAs (*p<0.05). (C) In vitro modulation of the function of hsa-miR-141 and hsa-miR-200c was done by inducing
synthetic mimic locked nucleic acid probes in the K19 negative PLC/PRF/5 HCC cell line. Target read-out of the induced miRNA expression was
done by means of qPCR and the data is presented as a log2 scale of the fold regulation of mimic/hairpin to negative control (**p<0.01; *p<0.05).
(D) Immunohistochemistry and in situ hybridisation on human HCC formalin-fixed paraffin-embedded samples for keratin 19 and miR-141. Left
panel shows the invading front of a K19-positive HCC, middle panel shows the center bulk of the K19-positive HCC, right panel shows the
surrounding tissue. Scale bars 200 mm. miR-141 expression strongly correlated with K19 expression in HCCs, and in the bile ducts (asterisk)/hepatic
progenitor cells (arrow) of the surrounding.
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could explain why K19 immunopositivity in HCC is clinically
relevant starting from only five per cent cell positivity, as those
K19-positive cells may be responsible for the chemoresistant/
stemness phenotype in these cancers.7 Moreover, disrupting the
HPC/biliary phenotype by diminishing K19/KRT19 expression,
rendered HCC cells more sensitive to cytotoxic agents as doxo-
rubicin, fluorouracil and sorafenib in vitro.
K19 by itself is neither an oncogene (as it is expressed in non-
malignant cells as well) nor is it a protein directly involved in
chemoresistance, but our data clearly showed that K19 is a crit-
ical player in the invasive and resistant behaviour of these sub-
types of HCCs. Additional partners are probably necessary to
support this specific function of K19. VASP and LAMB1 are
potential candidates, but also the presence of PDGFRA provides
us a possible explanation for the increased malignancy of
K19-positive HCCs. Several PDGFRA activation mutations have
been described to contribute to tumour initiation and progres-
sion. Identification and further understanding of K19-associated
genes might open horizons for a more patient-specific treatment,
for example, PDGFRA targeting by treatment with imatinib.24
Viewing the different molecular and epigenetic profile as well
as the distinct invasive properties of K19-positive HCCs, this
subclass of HCCs with adverse clinical outcome should be con-
sidered as a separate entity from the K19-negative HCCs in
daily clinical practice. Diagnostic pathology based on immuno-
histochemistry offers a fast, cheap and widely accessible method
to recognise this particular subclass of HCCs.
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